3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Neuroblastoma
2
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Myelodysplastic Syndromes
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Hodgkin Disease
1
Hepatoblastoma
1
Ganglioneuroblastoma
1
Interventions
Magnetic Resonance Spectroscopy
5
Cyclophosphamide
5
dinutuximab
3
Topotecan
3
Etoposide
3
Doxorubicin
3
Carboplatin
3
Biopsy
3
sargramostim
2
Vincristine
2
Thiotepa
2
Stem Cell Transplantation
2
Specimen Handling
2
Radiation
2
Platinum
2
Melphalan
2
Isotretinoin
2
Colony-Stimulating Factors
2
Cisplatin
2
1,2-diaminocyclohexaneplatinum II citrate
2
iberdomide
1
gallium Ga 68 dotatate
1
fludarabine
1
Watchful Waiting
1
Transurethral Resection of Bladder
1
Temozolomide
1
Razoxane
1
Radiotherapy
1
Proton Therapy
1
Observation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ganglioneuroblastoma
×
Influenza Vaccines
×
90 days
×
Clear all
NCT07502287
2026-03-30
DUAL-NK-NB
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled